CorMedix Inc. (CRMD)

NGM – Real Time Price. Currency in USD

7.51

-0.15 (-1.96%)

At close: May 12, 2026, 4:00 PM EDT

7.45

-0.06 (-0.79%)

After-hours: May 12, 2026, 7:41 PM EDT

07.05.2026

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

05.05.2026

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the market opens on Thursday, May 14, 2026, and will host a corporate update conference call at 8:30am Eastern Time.

27.04.2026

CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study

CorMedix Inc. (NASDAQ:CRMD) shares are up on Monday following the announcement of positive topline results from the Phase 3 ReSPECT trial assessing REZZAYO (rezafungin) for the prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic blood and marrow transplant.

27.04.2026

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 –

08.04.2026

CorMedix: A Shrinking Core And No Proven Second Engine

CorMedix is entering a post-TDAPA reset, with DefenCath revenue expected to decline materially and no proven second growth engine in place. FY26 guidance of ~$310M (midpoint) masks underlying deceleration, as DefenCath declines from $258.8M in FY25 to $150M–$170M in FY26, with the year-end run rate likely materially weaker heading into FY27. Rezzayo and DefenCath TPN offer long-term optionality but lack current financial contribution, while Melinta provides stability rather than growth.

07.04.2026

CorMedix to Participate in Needham Virtual Healthcare Conference

PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming 25th Annual Needham Virtual Healthcare Conference taking place April 13 – 16, 2026.

05.03.2026

CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript

Videos

No Data

There is no data to display

Press releases

27.04.2026

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 –

07.04.2026

CorMedix to Participate in Needham Virtual Healthcare Conference

05.03.2026

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J.

02.02.2026

CorMedix Therapeutics Announces Share Repurchase Program

BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company's outstanding common stock.

CorMedix Inc. (CRMD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

CorMedix Inc. (CRMD)

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

CorMedix: A Shrinking Core And No Proven Second Engine

CorMedix to Participate in Needham Virtual Healthcare Conference

CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript

Videos

No Data

Press releases

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

CorMedix to Participate in Needham Virtual Healthcare Conference

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

CorMedix Therapeutics Announces Share Repurchase Program

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

CorMedix: A Shrinking Core And No Proven Second Engine

CorMedix to Participate in Needham Virtual Healthcare Conference

CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript

Videos

No Data

Press releases

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

CorMedix to Participate in Needham Virtual Healthcare Conference

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

CorMedix Therapeutics Announces Share Repurchase Program

Search stocks

CorMedix Inc. (CRMD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

CorMedix Inc. (CRMD)

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

CorMedix: A Shrinking Core And No Proven Second Engine

CorMedix to Participate in Needham Virtual Healthcare Conference

CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript

Videos

No Data

Press releases

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

CorMedix to Participate in Needham Virtual Healthcare Conference

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

CorMedix Therapeutics Announces Share Repurchase Program

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

CorMedix: A Shrinking Core And No Proven Second Engine

CorMedix to Participate in Needham Virtual Healthcare Conference

CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript

Videos

No Data

Press releases

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

CorMedix to Participate in Needham Virtual Healthcare Conference

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

CorMedix Therapeutics Announces Share Repurchase Program